KR101402456B1 - Composition for antiobesity comprising phytoncide and conjugated linoleic acid - Google Patents

Abstract

The present invention provides a composition for anti-obesity comprising phytoncide and conjugated linoleic acid. Phytoncide significantly increases the anti-obesity effect of conjugated linoleic acid while decreasing ALT levels and triglyceride levels by the administration of conjugated linoleic acid. In addition, phytoncide increases the rate of active oxygen reduction and the resistance to active oxygen compared to the administration of conjugated linoleic acid alone. Accordingly, the composite composition comprising the conjugated linoleic acid and the phytoncide according to the present invention can increase the safety and efficacy of the conjugated linoleic acid, which is commercially available as an anti-obesity material.

Description

FIELD OF THE INVENTION The present invention relates to an antiobesity-containing phytoncide and conjugated linoleic acid,

The present invention relates to an anti-obesity composition comprising phytoncide and conjugated linoleic acid.

Conjugated linoleic acid (CLA) is a conjugated isomer of linoleic acid (LA), an essential fatty acid. It is a natural fatty acid component found in milk or muscle of ruminants. The conjugated linoleic acid has conjugated double bonds in the chain internals and in the trans arrangement at the cis-9 and trans-11 positions in the chain, or at the trans-10 and cis-12 positions, 9 and < RTI ID = 0.0 > trans-11 < / RTI > Conjugated linoleic acid has been shown to inhibit the development of atherosclerosis (Artery, 1997. 22: 266-277), enhance immune function (J. Nut. 1999. 129: 32-38), anticancer activity (Anticancer research 1997. 17: 969-973 ), Growth promotion (J. Nut., 2000. 130: 2981-2989), and diabetes mellitus, and showed a decrease in body fat (Am. J. Physiol., 1998. 275: R667-R672) . ≪ / RTI > In particular, the anti-obesity and anti-hyperlipidemic efficacy of conjugated linoleic acid has been extensively studied in animal experiments. This effect of conjugated linoleic acid is promoted by inhibiting the synthesis of fatty acids in the liver and promoting β-oxidation in brown adipose tissues and muscles . This effect was also studied in rodent experiments, where conjugated linoleic acid is produced by increased oxygen consumption and increased energy consumption. Conjugated linoleic acid, on the other hand, may exhibit side effects that lead to liver hypertrophy, which is due to the inhibition of lipid absorption by adipocytes and the accompanying accumulation of fat into the liver.

Although the anti-obesity effect of conjugated linoleic acid is well known in many literatures, research on the effect of the combination administration with other functional substances has not yet been actively studied.

It is an object of the present invention to provide a novel composition for anti-obesity which can improve the anti-obesity effect of conjugated linoleic acid while reducing side effects.

The present invention relates to a pharmaceutical composition for preventing or treating obesity comprising conjugated linoleic acid and phytoncide, a method of preventing or treating obesity comprising administering a therapeutically effective amount of conjugated linoleic acid and phytoncide to a subject, a conjugated linoleic acid And phytoncide. ≪ Desc / Clms Page number 2 >

As can be seen in the following examples, it was confirmed that the conjugate composition of conjugated linoleic acid and phytoncide not only exhibits an improved anti-obesity effect as compared with conjugated linoleic acid, but also reduces liver toxicity, which is a side effect of conjugated linoleic acid, and exhibits an antioxidative effect. Therefore, it has been confirmed through the present invention that phytoncide is preferably administered concomitantly to improve the safety of conjugated linoleic acid and the anti-obesity effect.

The conjugated linoleic acid used as an active ingredient in the pharmaceutical composition of the present invention is understood to include both conjugated linoleic acid and derivatives thereof. For example, free fatty acids and conjugated linoleic acid-glycerides of conjugated linoleic acid as derivatives of conjugated linoleic acid are also included in the scope of the present invention.

The conjugated linoleic acid used in the present invention can be obtained from ruminant or microorganism or can be synthesized organically, and a commercially available conjugated linoleic acid product is readily available to those skilled in the art.

In the pharmaceutical composition for preventing or treating obesity according to the present invention, the conjugated linoleic acid may be contained in an amount of 10 to 100 mg / kg / day. Preferably 20 to 80 mg / kg / day, more preferably 30 to 60 mg / kg / day. Depending on the number of daily administrations, the content may be adjusted considering a suitable dose per dose.

On the other hand, the phytoncide used as another active ingredient in the pharmaceutical composition of the present invention may be one extracted from cottonwood or white tea tree.

Methods for the extraction and purification of phytoncide are well known in the art, and those skilled in the art can easily use commercially available phytoncide products and use them in the present invention.

In the pharmaceutical composition for preventing or treating obesity according to the present invention, the phytoncide may be contained in an amount of 1 to 10 mg / kg / day. Preferably 2 to 8 mg / kg / day, more preferably 3 to 6 mg / kg / day. Depending on the number of daily administrations, the content may be adjusted considering a suitable dose per dose .

In the pharmaceutical composition of the present invention, the effective amount of conjugated linoleic acid and phytoncide means an amount required to achieve an anti-obesity effect. Such effective amount may vary depending on factors such as the type of disease, the severity of the disease, the type and amount of the active ingredient and other ingredients contained in the composition, the type of the formulation and the age, weight, general health status, sex and diet, The duration of the treatment, the drugs used concurrently, and the like. The conjugated linoleic acid and phytoncide of the pharmaceutical composition of the present invention may be administered once to several times a day, and may be administered in a dose of 10 to 100 mg / kg / day and 1 mg to 10 mg / kg / day, respectively have.

In the present invention, the 'object' includes, but is not limited to, a human, an orangutan, a chimpanzee, a mouse, a rat, a dog, a cow, a chicken, a pig,

The pharmaceutical composition of the present invention may be prepared by using pharmaceutically acceptable and physiologically acceptable adjuvants other than the conjugated linoleic acid and phytoncide, which are effective ingredients, and the adjuvants include excipients, disintegrants, sweeteners, binders, , A lubricant, a lubricant or a flavoring agent may be used.

The pharmaceutical composition of the present invention may be formulated into a pharmaceutical composition containing at least one pharmaceutically acceptable carrier in addition to the active ingredient for administration.

Acceptable pharmaceutical carriers for compositions that are formulated into a liquid solution include sterile water and sterile water suitable for the living body such as saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, One or more of these components may be mixed and used. If necessary, other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Further, it can be suitably formulated according to each disease or ingredient, using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.

The pharmaceutical preparation forms of the pharmaceutical composition of the present invention may be tablets, capsules, granules, powders, coated tablets, suppositories, syrups, juices, suspensions, emulsions, drips, liquids and sustained release formulations of active compounds .

The pharmaceutical composition of the present invention can be administered in a conventional manner via an oral or parenteral route.

The present invention also provides novel uses of conjugated compositions comprising conjugated linoleic acid and phytoncide for the manufacture of anti-obesity agents, methods of preventing or treating obesity comprising administering therapeutically effective amounts of conjugated linoleic acid and phytoncide to a subject. As described above, the conjugate composition of conjugated linoleic acid and phytoncide can be used for prevention or treatment of obesity.

The present invention also relates to a food composition for preventing or ameliorating obesity comprising conjugated linoleic acid and phytoncide, a method for preventing or improving obesity comprising administering an effective amount of conjugated linoleic acid and phytoncide to a subject, Linoleic acid, and phytoncide.

The food composition according to the present invention can be formulated in the same manner as the above pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectionery, diet bars, dairy products, meat, chocolate, pizza, ramen noodles, other noodles, gums, ice cream, .

For example, in the case where the food composition of the present invention is produced from a beverage such as a drink, it may further include citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, overbased plant extracts and various plant extracts in addition to the conjugated linoleic acid and phytoncide.

The present invention provides a health functional food comprising the composition for preventing or ameliorating obesity. Health functional foods are foods made by adding conjugated linoleic acid and phytoncide to food materials such as beverages, tea, spices, gum and confectionery, or by encapsulation, powdering, or suspension. When they are ingested, they have a certain health effect However, unlike general medicine, there is an advantage that there is no side effect that can occur when a long-term use of the medicine is performed using the food as a raw material. The health functional food of the present invention thus obtained is very useful because it can be ingested routinely. The amount of the conjugated linoleic acid and phytoncide added to such a health food can not be uniformly determined depending on the kind of the health food, but it may be added within a range that does not impair the original taste of the food, To 50% by weight, preferably 0.1 to 20% by weight. In the case of foods in the form of granules, tablets or capsules, they may be added usually in the range of 0.1 to 100% by weight, preferably 0.5 to 80% by weight. In one embodiment, the health functional food of the present invention may be in the form of a drink such as a drink.

The present invention also provides the use of said conjugated linoleic acid and phytoncide for the manufacture of a food for the prevention or amelioration of obesity. As described above, conjugated linoleic acid and phytoncide can be used for prevention or improvement of obesity.

Advantages and features of the present invention and methods of achieving them will become apparent with reference to the embodiments described in detail below. The present invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the concept of the invention to those skilled in the art. To fully disclose the scope of the invention to a person skilled in the art, and the invention is only defined by the scope of the claims.

Phytoncide significantly increases the anti-obesity effect of conjugated linoleic acid while reducing the increased ALT levels and triglyceride levels by the administration of conjugated linoleic acid. In addition, phytoncide increases the rate of active oxygen reduction and the resistance to active oxygen compared to the administration of conjugated linoleic acid alone. Accordingly, the composite composition comprising the conjugated linoleic acid and the phytoncide according to the present invention can enhance the safety and efficacy of the conjugated linoleic acid, which is commercially available as an anti-obesity material.

1 is a graph showing a change in body weight according to a dietary group.
2 is a graph showing changes in liver weight according to a dietary group.
FIG. 3 is a graph showing changes in the ALT value according to the dietary group. FIG.
4 is a graph showing the waist circumference reduction rate according to the dietary group.
5 is a graph showing body fat reduction rate according to a dietary group.
6 is a graph showing a weight loss rate according to a dietary group.
FIG. 7 is a graph showing the blood triglyceride reduction rate according to the dietary group.
8 is a graph showing the rate of reduction of active oxygen in the blood according to the dietary group.
FIG. 9 is a graph showing the rate of increase in blood reactive oxygen resistance according to the dietary group.

Advantages and features of the present invention and methods of achieving them will become apparent with reference to the embodiments described in detail below. The present invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the concept of the invention to those skilled in the art. To fully disclose the scope of the invention to a person skilled in the art, and the invention is only defined by the scope of the claims.

[ Example ]

The anti-obesity effect of a composition comprising conjugated linoleic acid and phytoncide was confirmed by animal experiments and human application tests.

Phytoncide is a product extracted from Thuja orientalis by SH Pharma Co. (Seoul, Korea), and the conjugated linoleic acid was purchased from HK Biotech Inc. with a purity of 80%. (Jinju, Korea).

Example  1: Through animal experiments Anti-obesity  Confirmation of effect

Six-week old male C57BL / 6J mice (Orient-Biolink Co., Sungnam, Korea) were randomly divided into the following five dietary groups (n = 8 per group) and fed a defined diet for 8 weeks. The experimental environment was 25 ± 2 ℃; Flashing time 12 hours; Lt; RTI ID = 0.0 > 50% < / RTI >

1) Reference feed + saline (control group),

2) High fat diet + saline ("HFD" group),

3) High fat diet + 2% CLA + saline ("HFD + CLA" group),

4) High fat diet + Phytoncide ("HFD + Phytoncide" group),

5) High fat diet + 2% CLA + phytoncide ("HFD + CLA + Phytoncide" group).

After 8 weeks of the experiment, mice were sacrificed, their weights were measured, their organs and plasma were separated, and liver weight, inguinal fat, serum (aspartic acid amino transferase (AST), alanine amino transferase Cholesterol, triglyceride), liver (total cholesterol, triglyceride), and active oxygen.

The experimental results are shown in the drawings and Table 1.

[Table 1]

1 is a graph showing a change in body weight according to a dietary group. As can be seen from FIG. 1, it was confirmed that conjugated linoleic acid decreased the weight gain of the mice due to the high fat diet, and phytoncide did not affect the anti-obesity effect when administered alone, but was administered in combination with conjugated linoleic acid , It was found that phytoncide enhances the anti-obesity effect of conjugated linoleic acid.

2 is a graph showing changes in liver weight according to a dietary group. As can be seen in FIG. 2, liver hypertrophy occurred in the high-fat diet system in which conjugated linoleic acid was administered, but it was confirmed that the liver hypertrophy was reduced when the conjugated linoleic acid and phytoncide were administered in combination.

FIG. 3 is a graph showing changes in the ALT value according to the dietary group. FIG. As can be seen from FIG. 3, hepatic toxicity was induced in the high-fat diet system in which conjugated linoleic acid was administered, but it was confirmed that such hepatic toxicity was reduced when the conjugated linoleic acid and phytoncide were administered in combination.

In conclusion, the combination of conjugated linoleic acid and phytoncide showed a significant weight loss effect compared with the control group administered with the high fat diet alone, and phytoncide synergism with conjugated linoleic acid was shown against weight reduction. In addition, the weight of the liver increased by conjugated linoleic acid was decreased by phytoncide, and decreased ALT levels and neutrophil phytoncide in the liver by conjugated linoleic acid. Based on these results, it can be seen that phytoncide counteracts hepatotoxicity caused by conjugated linoleic acid, which is applied for anti-obesity effect.

Example  2: Through human experiment Anti-obesity  Confirmation of effect

Overweight women were recruited by physical and medical health status and lifestyle research. Selection exclusion criteria are smoking, hypertension, arteriosclerosis, drug use, and intense exercise for more than 10 hours during the week if the BMI exceeds or falls below the range of 27-30 kg / m ² . All the volunteers were trained to maintain the same physical activity during the experiment and the calories consumed ranged from 18-47% (mean 30E%), 10-23% (mean 13E%), 40-70% (average 53E% (Average 1,500 kcal). This experiment was conducted according to the experimental method presented by the Korea Food & Drug Administration 's Research Ethics Committee (IRB).

Thirty (30) overweight women were randomly divided into three dietary groups (n = 10 per group) and fed a defined diet for 12 weeks.

1) saline (control group),

2) 800 mg CLA ("CLA" group),

3) 750 mg CLA + 50 mg phytoncide ("CLA + Phytoncide" group)

Table 2 shows the baseline values for the participants in each dietary group.

[Table 2]

Body weight, body fat, triglyceride, cholesterol, reactive oxygen, and reactive oxygen storage capacity of overweight women participating in the experiment were observed for 12 weeks.

4 is a graph showing the waist circumference reduction rate according to the dietary group. As can be seen from Fig. 4, the waist circumference reduction rate of the conjugate linoleic acid-phytoncide combination group was higher than that of the conjugate linoleic acid alone group.

5 is a graph showing body fat reduction rate according to a dietary group. As can be seen from FIG. 5, the body fat reduction rate of the conjugated linoleic acid-phytoncide combination group was higher than that of the conjugated linoleic acid alone group.

6 is a graph showing a weight loss rate according to a dietary group. As can be seen from FIG. 6, the body fat reduction rate of the conjugated linoleic acid-phytoncide combination group was higher than that of the conjugated linoleic acid alone group.

FIG. 7 is a graph showing the blood triglyceride reduction rate according to the dietary group. As can be seen from FIG. 7, the group of conjugated linoleic acid and phytoncide administered in combination showed a greater decrease in serum triglyceride than the conjugated linoleic acid alone group.

8 is a graph showing the rate of reduction of active oxygen in the blood according to the dietary group. As can be seen from Fig. 8, the group treated with conjugated linoleic acid and phytoncide in combination showed a higher rate of decrease in oxygen radical activity than the conjugated linoleic acid alone group.

FIG. 9 is a graph showing the rate of increase in blood reactive oxygen resistance according to the dietary group. As can be seen from Fig. 9, the group of conjugated linoleic acid and phytoncide administered together showed a higher rate of increase in blood-reactive oxygen resistance than the conjugated linoleic acid alone group.

In conclusion, the combination of conjugated linoleic acid with phytoncide showed higher anti - obesity effect on all the indexes except serum cholesterol such as waist circumference, body fat, body weight, and blood triglyceride as compared with the conjugate linoleic acid alone group. In addition, active oxygen reduction rate and active oxygen resistance were further increased in the combination feed. Based on these results, it can be seen that the conjugated linoleic acid-phytoncide compound, which increases the anti-obesity effect of conjugated linoleic acid and counteracts adverse effects, is an effective anti-obesity material.

Claims (10)

Conjugated linoleic acid, and phytoncide.
The method according to claim 1,
Wherein the conjugated linoleic acid is contained in an amount of 10 to 100 mg / kg / day.
The method according to claim 1,
Wherein the phytoncide is contained in an amount of 1 to 10 mg / kg / day.
The method according to claim 1,
Wherein the phytoncide is extracted from a cottonwood or a spruce tree.
The method according to claim 1,
Wherein the phytoncide is contained in a proportion of 5 to 10 parts by weight based on 100 parts by weight of the conjugated linoleic acid.
A conjugated linoleic acid, and phytoncide.
The method according to claim 6,
Wherein the conjugated linoleic acid is contained in an amount of 10 to 100 mg / kg / day.
The method according to claim 6,
Wherein the phytoncide is contained in an amount of 1 to 10 mg / kg / day.
The method according to claim 6,
Wherein the phytoncide is extracted from an opacified or perennial plant.
The method according to claim 6,
Wherein the phytoncide is contained in a proportion of 5 to 10 parts by weight based on 100 parts by weight of the conjugated linoleic acid.

Images